Current challenges in prostate cancer management and the rationale behind targeted focal therapy

Advances in Urology

Volumn , Issue , 2012, Pages

  Barqawi, Al B ^a   Krughoff, Kevin J ^a   Eid, Khadijah ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862282896     PISSN: 16876369     EISSN: 16876377     Source Type: Journal    
DOI: 10.1155/2012/862639     Document Type: Review

References (69)

1. Jemal A., Siegel R., Xu J., Ward E., Cancer statistics, 2010 CA Cancer Journal for Clinicians 2010 60 5 277 300
2. Siegel R., Ward E., Brawley O., Jemal A., Cancer statistics, 2011 CA Cancer Journal for Clinicians 2011 61 4 212 236
3. Howlader N., Noone A. M., Krapcho M., Neyman N., Aminou R., SEER Cancer Statistics Review, 19752008 Bethesda, Md, USA National Cancer Institute. 2011, http://seer.cancer.gov/csr/19752008/
4. American Cancer Society, Cancer Facts and Figures Atlanta, Ga, USA American Cancer Society. 2010, http://www.cancer.org/Research/ CancerFactsFigures/CancerFactsFigures/cancer-facts-figures-2011
5. Gulati R., Wever E. M., Tsodikov A., Penson D. F., Inoue L. Y. T., Katcher J., Lee S. Y., Heijnsdijk E. A. M., Draisma G., De Koning H. J., Etzioni R., What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models Cancer Epidemiology Biomarkers and Prevention 2011 20 5 740 750
6. Potosky A. L., Miller B. A., Albertsen P. C., Kramer B. S., The role of increasing detection in the rising incidence of prostate cancer Journal of the American Medical Association 1995 273 7 548 552
7. Etzioni R., Penson D. F., Legler J. M., Di Tommaso D., Boer R., Gann P. H., Feuer E. J., Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends Journal of the National Cancer Institute 2002 94 13 981 990 (Pubitemid 34814727)
8. Stephenson R. A., Smart C. R., Mineau G. P., James B. C., Janerich D. T., Dibble R. L., The fall in incidence of prostate carcinoma: on the down side of a prostate specific antigen induced peak in incidence-data from the Utah cancer registry Cancer 1996 77 7 1342 1348 (Pubitemid 26102334)
9. Stamey T. A., Yang N., Hay A. R., McNeal J. E., Freiha F. S., Redwine E., Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate New England Journal of Medicine 1987 317 15 909 916 (Pubitemid 17147932)
10. Welch H. G., Albertsen P. C., Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 19862005 Journal of the National Cancer Institute 2009 101 19 1325 1329
11. Stamey T. A., Caldwell M., McNeal J. E., Nolley R., Hemenez M., Downs J., The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? Journal of Urology 2004 172 4I 1297 1301 (Pubitemid 39249701)
12. Thompson I. M., Ankerst D. P., Chi C., Lucia M. S., Goodman P. J., Crowley J. J., Parnes H. L., Coltman C. A., Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower Journal of the American Medical Association 2005 294 1 66 70 (Pubitemid 41002840)
13. Chodak G. W., Schoenberg H. W., Progress and problems in screening for carcinoma of the prostate World Journal of Surgery 1989 13 1 60 64 (Pubitemid 19043570)
14. Etzioni R., Cha R., Feurer E., Davidov O., Asymptomatic incidence and duration of prostate cancer American Journal of Epidemiology 1998 148 775 785 (Pubitemid 28485287)
15. Ries L. A. G., Eisner M. P., Kosary C. L., Hankey B. F., Miller B. A., SEER Cancer Statistics Review, 19731999 Bethesda, MD, USA National Cancer Institute. http://seer.cancer.gov/csr/19731999/prostate.pdf
16. Fedeli U., Alba N., Ciccone G., Galassi C., Spolaore P., Re: trends in radical prostatectomy rates Journal of the National Cancer Institute 2007 99 13 1052 1053
17. Ellison L. M., Heaney J. A., Birkmeyer J. D., Trends in the use of radical prostatectomy for treatment of prostate cancer Effective Clinical Practice 1999 2 5 228 233
18. Hankey B. F., Feuer E. J., Clegg L. X., Hayes R. B., Legler J. M., Prorok P. C., Ries L. A., Merrill R. M., Kaplan R. S., Cancer surveillance series: interpreting trends in prostate cancerpart I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates Journal of the National Cancer Institute 1999 91 12 1017 1024 (Pubitemid 29293040)
19. Hoffman R. M., Zeliadt S. B., The cautionary tale of PSA testing: comment on Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0nm/mL Archives of Internal Medicine 2010 170 1262 1263
20. Carter H. B., Piantadosi S., Isaacs J. T., Clinical evidence for and implications of the multistep development of prostate cancer Journal of Urology 1990 143 4 742 746 (Pubitemid 20112094)
21. Franks L. M., Latent carcinoma of the prostate The Journal of Pathology and Bacteriology 1954 68 2 603 616
22. Ankerst D. P., Thompson I. M., Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification Archivio Italiano di Urologia e Andrologia 2006 78 4 125 129 (Pubitemid 46113686)
23. Labrie F., Dupont A., Suburu R., Cusan L., Tremblay M., Gomez J. L., Emond J., Serum prostate specific antigen as pre-screening test for prostate cancer Journal of Urology 1992 147 3 846 852
24. Bartsch G., Horninger W., Klocker H., Pelzer A., Bektic J., Oberaigner W., Schennach H., Schfer G., Frauscher F., Boniol M., Severi G., Robertson C., Boyle P., Tyrol prostate cancer demonstration project: early detection, treatment, outcome, incidence and mortality British Journal of Urology International 2008 101 7 809 816 (Pubitemid 351347736)
25. Cooperberg M. R., Lubeck D. P., Mehta S. S., Carroll P. R., Kantoff P. W., Smith M. R., Roach M., D'Amico A. V., Iversen P., Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE) Journal of Urology 2003 170 6 S21 S27
26. Polascik T. J., Mayes J. M., Sun L., Madden J. F., Moul J. W., Mouraviev V., Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy The Prostate 2008 68 13 1380 1386
27. Heijnsdijk E. A., der Kinderen A., Wever E. M., Draisma G., Roobol M. J., De Koning H. J., Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer The British Journal of Cancer 2009 101 11 1833 1838
28. Draisma G., Boer R., Otto S. J., van der Cruijsen I. W., Damhuis R. A. M., Schrder F. H., de Koning H. J., Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer Journal of the National Cancer Institute 2003 95 12 868 878 (Pubitemid 36833878)
29. Reed A. B., Parekh D. J., Biomarkers for prostate cancer detection Expert Review of Anticancer Therapy 2010 10 1 103 114
30. Chodak G., Prostate cancer: epidemiology, screening, and biomarkers Reviews in Urology 2006 8 Supplement 2 S3 S8
31. Sreekumar A., Poisson L. M., Rajendiran T. M., Khan A. P., Cao Q., Yu J., Laxman B., Mehra R., Lonigro R. J., Li Y., Nyati M. K., Ahsan A., Kalyana-Sundaram S., Han B., Cao X., Byun J., Omenn G. S., Ghosh D., Pennathur S., Alexander D. C., Berger A., Shuster J. R., Wei J. T., Varambally S., Beecher C., Chinnaiyan A. M., Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression Nature 2009 457 7231 910 914
32. Penson D. F., Active surveillance: not your father's watchful waiting. Oncology 2009 23 11 980 981
33. van den Bergh R. C. N., Roemeling S., Roobol M. J., Aus G., Hugosson J., Rannikko A. S., Tammela T. L., Bangma C. H., Schrder F. H., Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly European Urology 2009 55 1 1 8
34. Ross A. E., Loeb S., Landis P., Partin A. W., Epstein J. I., Kettermann A., Feng Z., Carter H. B., Walsh P. C., Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program Journal of Clinical Oncology 2010 28 17 2810 2816
35. Suardi N., Capitanio U., Chun F. K. H., Graefen M., Perrotte P., Schlomm T., Haese A., Huland H., Erbersdobler A., Montorsi F., Karakiewicz P. I., Currently used criteria for active surveillance in men with low-risk prostate cancer Cancer 2008 113 8 2068 2072
36. McCormick K. M., A concept analysis of uncertainty in illness Journal of Nursing Scholarship 2002 34 2 127 131 (Pubitemid 41719881)
37. Gray R. E., Fitch M., Phillips C., Labrecque M., Fergus K., To tell or not to tell: patterns of disclosure among men with prostate cancer Psycho-Oncology 2000 9 4 273 282 (Pubitemid 30649354)
38. Lintz K., Moynihan C., Steginga S., Norman A., Eeles R., Huddart R., Dearnaley D., Watson M., Prostate cancer patients' support and psychological care needs: survey from a non-surgical oncology clinic Psycho-Oncology 2003 12 8 769 783 (Pubitemid 38040029)
39. Gwede C., Pow-Sang J., Seigne J., Heysek R., Helal M., Shade K., Cantor A., Jacobsen P. B., Treatment decision-making strategies and influences in patients with localized prostate carcinoma Cancer 2005 104 7 1381 1390 (Pubitemid 41356153)
40. Denberg T. D., Melhado T. V., Steiner J. F., Patient treatment preferences in localized prostate carcinoma: the influence of emotion, misconception, and anecdote Cancer 2006 107 3 620 630 (Pubitemid 44107224)
41. Chapple A., Ziebland S., Herxheimer A., Mcpherson A., Shepperd S., Miller R., Is watchful waiting a real choice for men with prostate cancer? A qualitative study British Journal of Urology International 2002 90 3 257 264 (Pubitemid 34989073)
42. Latini D. M., Hart S. L., Knight S. J., Cowan J. E., Ross P. L., DuChane J., Carroll P. R., The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance Journal of Urology 2007 178 3 826 832 (Pubitemid 47224948)
43. Mazur D. J., Hickam D. H., Mazur M. D., How patients' preferences for risk information influence treatment choice in a case of high risk and high therapeutic uncertainty: asymptomatic localized prostate cancer Medical Decision Making 1999 19 4 394 398 (Pubitemid 29474765)
44. Wilt T. J., Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer Seminars in Urologic Oncology 2002 20 1 10 17 (Pubitemid 34132321)
45. Denberg T. D., Melhado T. V., Steiner J. F., Patient treatment preferences in localized prostate carcinoma: the influence of emotion, misconception, and anecdote Cancer 2006 107 3 620 630 (Pubitemid 44107224)
46. Mazur D. J., Hickam D. H., Patient preferences for management of localized prostate cancer Western Journal of Medicine 1996 165 1-2 26 30 (Pubitemid 26314037)
47. Harlan L. C., Potosky A., Gilliland F. D., Hoffman R., Albertsen P. C., Hamilton A. S., Eley J. W., Stanford J. L., Stephenson R. A., Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study Journal of the National Cancer Institute 2001 93 24 1864 1871 (Pubitemid 34048653)
48. Schrder F. H., Hugosson J., Roobol M. J., Tammela T. L. J., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L. J., Recker F., Mpttnen A. B., Bangma C. H., Aus G., Villers A., Rebillard X., Van Kwast T. D., Blijenberg B. G., Moss S. M., De Koning H. J., Auvinen A., Screening and prostate-cancer mortality in a randomized european study New England Journal of Medicine 2009 360 13 1320 1328
49. Smith M. R., Effective treatment for early-stage prostate cancerpossible, necessary, or both? New England Journal of Medicine 2011 364 18 1770 1772
50. McGregor M., Hanley J. A., Boivin J. F., McLean R. G., Screening for prostate cancer: estimating the magnitude of overdetection Canadian Medical Association Journal 1998 159 11 1368 1372 (Pubitemid 29002427)
51. Wilt T. J., The VA/NCI/AHRQ CSP#407: prostate cancer intervention versus observation trial (PIVOT): main results from a randomized trial comparing radical prostatectomy to watchful waiting in men with clinically localized prostate cancer Proceedings of the Plenary Session of the American Urological Association Annual Meeting 2011 Washington, DC, USA
52. Harris R., Lohr K., Screening for prostate cancer: an update of the evidence for the U.S. preventive services task force Annals of Internal Medicine 2002 137 11 917 929 (Pubitemid 35416628)
53. Kundu S. D., Roehl K. A., Eggener S. E., Antenor J. A., Han M., Catalona W. J., Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies Journal of Urology 2004 172 6 I 2227 2231 (Pubitemid 39507497)
54. Madalinska J. B., Essink-Bot M. L., De Koning H. J., Kirkels W. J., Van der Maas P. J., Schrder F. H., Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer Journal of Clinical Oncology 2001 19 6 1619 1628 (Pubitemid 32230861)
55. Humphreys M. R., Gettman M. T., Chow G. K., Zincke H., Blute M. L., Minimally invasive radical prostatectomy Mayo Clinic Proceedings 2004 79 9 1169 1180 (Pubitemid 39129481)
56. Hu J. C., Gu X., Lipsitz S. R., Barry M. J., D'Amico A. V., Weinberg A. C., Keating N. L., Comparative effectiveness of minimally invasive vs open radical prostatectomy Journal of the American Medical Association 2009 302 14 1557 1564
57. Sanda M. G., Dunn R. L., Michalski J., Sandler H. M., Northouse L., Hembroff L., Lin X., Greenfield T. K., Litwin M. S., Saigal C. S., Mahadevan A., Klein E., Kibel A., Pisters L. L., Kuban D., Kaplan I., Wood D., Ciezki J., Shah N., Wei J. T., Quality of life and satisfaction with outcome among prostate-cancer survivors New England Journal of Medicine 2008 358 12 1250 1261 (Pubitemid 351439226)
58. Kao J., Cesaretti J. A., Stone N. N., Stock R. G., Update on prostate brachytherapy: long-term outcomes and treatment-related morbidity Current Urology Reports 2011 12 3 237 242
59. Ahmed H. U., Emberton M., Is focal therapy the future for prostate cancer? Future Oncology 2010 6 2 261 268
60. Ahmed H. U., Moore C., Emberton M., Minimally-invasive technologies in uro-oncology: the role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer Surgical Oncology 2009 18 3 219 232
61. Lindner U., Lawrentschuk N., Trachtenberg J., Image guidance for focal therapy of prostate cancer World Journal of Urology 2010 28 6 727 734
62. Ward J. F., Contemporary outcomes of focal therapy in prostate cancer: what do we know so far... World Journal of Urology 2010 28 5 593 597
63. Chaussy C., Throff S., High-intensity focused ultrasound in the management of prostate cancer Expert Review of Medical Devices 2010 7 2 209 217
64. Bostwick D. G., Waters D. J., Farley E. R., Meiers I., Rukstalis D., Cavanaugh W. A., Ragde H., Dineen M. K., Bahn D., Scionti S., Babian R., Ellis D. S., Rewcastle J. C., Burke H. B., Andriole G. L., Onik G., Barqawi A. E., Maksem J., Barzell W. E., Group consensus reports from the consensus conference on focal treatment of prostatic carcinoma, celebration, florida, february 24, 2006 Urology 2007 70 6 S42 S44
65. Crawford E. D., Wilson S. S., Torkko K. C., Hirano D., Stewart J. S., Brammell C., Wilson R. S., Kawata N., Sullivan H., Lucia M. S., Werahera P. N., Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy British Journal of Urology International 2005 96 7 999 1004 (Pubitemid 41531402)
66. Barqawi A. B., Rove K. O., Gholizadeh S., O'Donnell C. I., Koul H., Crawford E. D., The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer Journal of Urology 2011 186 1 80 85
67. Crawford E. D., Barqawi A. B., Targeted focal therapy: a minimally invasive ablation technique for early prostate cancer Oncology 2007 21 1 27 32 (Pubitemid 46242753)
68. Lazzeri M., Guazzoni G., Focal therapy meets prostate cancer The Lancet 2010 376 9746 1036 1037
69. Barqawi A. B., Maroni P. D., Crawford E. D., Ahmed H. U., Arya M., Carroll P., Emberton M., Determining success of focal therapy: biochemical and biopsy strategies Focal Therapy in Prostate Cancer 2012 1st Blackwell Publishing Company